Viking Therapeutics (VKTX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.55

Estimate

-$1.06

Surprise

-46.2%

Score today

4.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Viking Therapeutics (VKTX) reported a wider loss than forecast — adjusted EPS of -$1.55 against the -$1.06 estimate (a 46.2% shortfall).

• Viking Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-10-28
• Viking Therapeutics Q3 EPS $(1.55) Misses $(1.07) Estimate — benzinga, 2026-10-28
• 10 Health Care Stocks Whale Activity In Today’s Session — benzinga, 2026-10-28

TrendMatrix currently rates VKTX Sell at 4.5/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -46.2% surprise compares with a -35.2% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$25.36

Price target

$31.83

Stop

$23.58

Upside to target

+25.5%

Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$3.22B

P/E (fwd)

-5.8

52-week range

$23.82–$43.15

Off 52-week high

41.2%

RSI (14)

41

Volume vs avg

0.81×

Score today

4.5/10